cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.21023910.v1
title: Post-ERCP pancreatitis occurs more frequently in self-expandable metallic stents than multiple plastic stents on benign biliary strictures: a meta-analysis

description: The occurrence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) after using covered self-expandable metallic stents (CSEMS) and multiple plastic stents (MPS) in the therapy of benign biliary strictures (BBS) remains ambiguous, this analysis aimed to evaluate the outcomes. A systematic search of electronic databases (PubMed, Web of Science and Cochrane Library) was conducted for randomised controlled trials (RCTs), and the included studies were published between 2008 and 2021. The primary outcome was PEP, while the secondary outcomes were stricture resolution, recurrence, overall adverse events, costs, and ERCP sessions. Pooled effect sizes were calculated with the random-effects model or fixed-effects model depending on the heterogeneity. Six RCTs contained 444 patients (221 with CSEMS, 223 with MPS) finally included in the meta-analysis. The present analysis shows that compared to MPS, PEP is more likely to occur in CSEMS (OR [odds ratio] = 3.34, 95% confidence intervals [CI]:1.44–7.77, <i>p</i> = .005). CSEMS needs fewer ERCP sessions (Mean Deviation [MD]: −1.56; 95%CI:−2.66, −0.46], <i>p</i> = .006). The difference in stricture resolution and recurrence was not significant between the two stent types (OR = 0.87, 95%CI: 0.49–1.56, <i>p</i> = .64; and OR = 2.3, 95%CI: 0.68–7.76, <i>p</i> = .18). The incidence of overall adverse events was comparable between CSEMS and the MPS group (OR = 1.49, 95% CI: 0.97–2.29, <i>p</i> = .07). Compared with MPS, CSEMS caused a significantly higher incidence of PEP but fewer ERCP procedures, while the rate of stricture resolution, recurrence, and overall adverse events were comparable. Prevention methods of PEP should be further evaluated in BBS when undergoing CSEMS placement. PROSPERO CRD42022314864.
Key messagesCSEMS and MPS placement remain a mainstay for patients with BBS, and severe complications after stent placement have not been compared.The incidence of PEP was higher after deployment of CSEMS compared to MPS.Prevention methods of PEP should be evaluated in BBS when undergoing CSEMS placement. CSEMS and MPS placement remain a mainstay for patients with BBS, and severe complications after stent placement have not been compared. The incidence of PEP was higher after deployment of CSEMS compared to MPS. Prevention methods of PEP should be evaluated in BBS when undergoing CSEMS placement.
DOI: 10.6084/m9.figshare.19307319
title: Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model

description: <b>Background:</b> Previous studies have proven that Purinostat Mesylate (PM) is a new HDAC inhibitor and exhibits significant antitumor efficacy. However, the clinical application of PM was greatly limited by its poor solubility in water and low bioavailability. <b>Objective:</b>To increase the solubility of PM through pharmaceutical research, and prepare it into an injection that meets the needs of intravenous use to promote its clinical application. <b>Methods</b>The prepared PM/HP-β-CD inclusion complex was studied by computer simulation, fourier transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (1H-NMR spectroscopy), and scanning electron microscopy (SEM). Then, the antitumor effects of PM/HP-β-CD inclusion complex were studied by in vitro cytotoxicity assay, apoptosis assay, pharmacokinetic study and in vivo antitumor assay. <b>Results:</b>Phase Solubility Analysis revealed that PM and HP-β-CD were compatible and the solubility of PM increased almost 220 times, to 2.02 mg/mL. The interaction mechanism studies revealed that PM could be embedded into the cavity of HP-β-CD through the side of the aminobenzene ring. Cell viability and apoptosis assays showed that PM/HP-β-CD complex maintained the good anti-cancer activity of PM, and PM/HP-β-CD complex has a better anti-tumor effect and lower toxicity than LBH589 and Hyper-CVAD/RTX in vivo. All the results suggest that HP-β-CD can solve the problem of PM administration and provide a way for clinical application of PM. <b>Conclusions:</b> In this study, an injectable formulation of PM in HP-β-CD (10% w/v) was prepared to improve its water solubility. Our research provides a way for clinical administration of PM, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related hematologic malignancies in China and the USA.KEY MESSAGESWe developed a preparation of Purinostat Mesylate that can be administered intravenously, reducing the toxicity associated with oral administration.This preparation has an outstanding therapeutic effect on SU-DHL-6 xenograft tumour, indicating its clinical value, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related haematologic malignancies in China and the USA. We developed a preparation of Purinostat Mesylate that can be administered intravenously, reducing the toxicity associated with oral administration. This preparation has an outstanding therapeutic effect on SU-DHL-6 xenograft tumour, indicating its clinical value, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related haematologic malignancies in China and the USA.
DOI: 10.6084/m9.figshare.19307319.v1
title: Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model

description: <b>Background:</b> Previous studies have proven that Purinostat Mesylate (PM) is a new HDAC inhibitor and exhibits significant antitumor efficacy. However, the clinical application of PM was greatly limited by its poor solubility in water and low bioavailability. <b>Objective:</b>To increase the solubility of PM through pharmaceutical research, and prepare it into an injection that meets the needs of intravenous use to promote its clinical application. <b>Methods</b>The prepared PM/HP-β-CD inclusion complex was studied by computer simulation, fourier transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (1H-NMR spectroscopy), and scanning electron microscopy (SEM). Then, the antitumor effects of PM/HP-β-CD inclusion complex were studied by in vitro cytotoxicity assay, apoptosis assay, pharmacokinetic study and in vivo antitumor assay. <b>Results:</b>Phase Solubility Analysis revealed that PM and HP-β-CD were compatible and the solubility of PM increased almost 220 times, to 2.02 mg/mL. The interaction mechanism studies revealed that PM could be embedded into the cavity of HP-β-CD through the side of the aminobenzene ring. Cell viability and apoptosis assays showed that PM/HP-β-CD complex maintained the good anti-cancer activity of PM, and PM/HP-β-CD complex has a better anti-tumor effect and lower toxicity than LBH589 and Hyper-CVAD/RTX in vivo. All the results suggest that HP-β-CD can solve the problem of PM administration and provide a way for clinical application of PM. <b>Conclusions:</b> In this study, an injectable formulation of PM in HP-β-CD (10% w/v) was prepared to improve its water solubility. Our research provides a way for clinical administration of PM, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related hematologic malignancies in China and the USA.KEY MESSAGESWe developed a preparation of Purinostat Mesylate that can be administered intravenously, reducing the toxicity associated with oral administration.This preparation has an outstanding therapeutic effect on SU-DHL-6 xenograft tumour, indicating its clinical value, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related haematologic malignancies in China and the USA. We developed a preparation of Purinostat Mesylate that can be administered intravenously, reducing the toxicity associated with oral administration. This preparation has an outstanding therapeutic effect on SU-DHL-6 xenograft tumour, indicating its clinical value, which has been under phase I clinical trial for the treatment of relapsed or refractory B-cell-related haematologic malignancies in China and the USA.
DOI: 10.6084/m9.figshare.21656298
title: Different treatment response to systemic corticosteroids according to white blood cell counts in severe COVID-19 patients

description: Limited data are available in COVID-19 patients on the prediction of treatment response to systemic corticosteroid therapy based on systemic inflammatory markers. There is a concern whether the response to systemic corticosteroid is different according to white blood cell (WBC) counts in COVID-19 patients. We aimed to assess whether WBC count is related with the clinical outcomes after treatment with systemic corticosteroids in severe COVID-19. We conducted a retrospective cohort study and analysed the patients hospitalised for severe COVID-19 and received systemic corticosteroids between July 2020 and June 2021. The primary endpoint was to compare the composite poor outcome of mechanical ventilation, extracorporeal membrane oxygenation, and mortality among the patients with different WBC counts. Of the 585 COVID-19 patients who required oxygen supplementation and systemic corticosteroids, 145 (24.8%) belonged to the leukopoenia group, 375 (64.1%) belonged to the normal WBC group, and 65 (11.1%) belonged to the leukocytosis group. In Kaplan-Meier curve, the composite poor outcome was significantly reduced in leukopoenia group compared to leukocytosis group (log-rank <i>p</i>-value &lt; 0.001). In the multivariable Cox regression analysis, leukopoenia group was significantly associated with a lower risk of the composite poor outcome compared to normal WBC group (adjusted hazard ratio [aHR] = 0.32, 95% CI 0.14–0.76, <i>p</i>-value = 0.009) and leukocytosis group (aHR = 0.30, 95% CI = 0.12–0.78, <i>p</i>-value = 0.013). There was no significant difference in aHR for composite poor outcome between leukocytosis and normal WBC group. Leukopoenia may be related with a better response to systemic corticosteroid therapy in COVID-19 patients requiring oxygen supplementation.KEY MESSAGESIn severe COVID-19 treated with systemic corticosteroids, patients with leukopoenia showed a lower hazard for composite poor outcome compared to patients with normal white blood cell counts or leukocytosis.Leukopoenia may be a potential biomarker for better response to systemic corticosteroid therapy in COVID-19 pneumonia. In severe COVID-19 treated with systemic corticosteroids, patients with leukopoenia showed a lower hazard for composite poor outcome compared to patients with normal white blood cell counts or leukocytosis. Leukopoenia may be a potential biomarker for better response to systemic corticosteroid therapy in COVID-19 pneumonia.
DOI: 10.6084/m9.figshare.21656298.v1
title: Different treatment response to systemic corticosteroids according to white blood cell counts in severe COVID-19 patients

description: Limited data are available in COVID-19 patients on the prediction of treatment response to systemic corticosteroid therapy based on systemic inflammatory markers. There is a concern whether the response to systemic corticosteroid is different according to white blood cell (WBC) counts in COVID-19 patients. We aimed to assess whether WBC count is related with the clinical outcomes after treatment with systemic corticosteroids in severe COVID-19. We conducted a retrospective cohort study and analysed the patients hospitalised for severe COVID-19 and received systemic corticosteroids between July 2020 and June 2021. The primary endpoint was to compare the composite poor outcome of mechanical ventilation, extracorporeal membrane oxygenation, and mortality among the patients with different WBC counts. Of the 585 COVID-19 patients who required oxygen supplementation and systemic corticosteroids, 145 (24.8%) belonged to the leukopoenia group, 375 (64.1%) belonged to the normal WBC group, and 65 (11.1%) belonged to the leukocytosis group. In Kaplan-Meier curve, the composite poor outcome was significantly reduced in leukopoenia group compared to leukocytosis group (log-rank <i>p</i>-value &lt; 0.001). In the multivariable Cox regression analysis, leukopoenia group was significantly associated with a lower risk of the composite poor outcome compared to normal WBC group (adjusted hazard ratio [aHR] = 0.32, 95% CI 0.14–0.76, <i>p</i>-value = 0.009) and leukocytosis group (aHR = 0.30, 95% CI = 0.12–0.78, <i>p</i>-value = 0.013). There was no significant difference in aHR for composite poor outcome between leukocytosis and normal WBC group. Leukopoenia may be related with a better response to systemic corticosteroid therapy in COVID-19 patients requiring oxygen supplementation.KEY MESSAGESIn severe COVID-19 treated with systemic corticosteroids, patients with leukopoenia showed a lower hazard for composite poor outcome compared to patients with normal white blood cell counts or leukocytosis.Leukopoenia may be a potential biomarker for better response to systemic corticosteroid therapy in COVID-19 pneumonia. In severe COVID-19 treated with systemic corticosteroids, patients with leukopoenia showed a lower hazard for composite poor outcome compared to patients with normal white blood cell counts or leukocytosis. Leukopoenia may be a potential biomarker for better response to systemic corticosteroid therapy in COVID-19 pneumonia.
DOI: 10.6084/m9.figshare.19962683
title: The causal relationships between obstructive sleep apnea and elevated CRP and TNF-α protein levels

description: Obstructive sleep apnea (OSA) and inflammation are closely related. This study aimed to evaluate the associations and causal effect between C-reactive protein (CRP) and tumour necrosis factor-alpha (TNF-α) levels and OSA. Pooled analysis was conducted to compare the expression differences of CRP and TNF-α between OSA patients with different severity and controls, and between continuous positive airway pressure (CPAP) and non-CPAP interventions for OSA patients. Using published GWAS summary statistics, we conducted a bidirectional two-sample Mendelian Randomization (MR) to estimate the causal relationships between CRP and TNF-α levels and OSA risk. Effect estimates were evaluated using inverse-variance weighted (IVW) as primary method, and several other MR methods as sensitivity analysis. Both TNF-α (WMD [95%CI] = 5.86 [4.80–6.93] pg/ml, <i>p</i> &lt; .00001) and CRP (WMD [95%CI] = 2.66 [2.15–3.17] mg/L, <i>p</i> &lt; .00001), showed a significant increase in OSA patients compared with controls and this increasing trend was associated with OSA severity. Besides, compared to blank control (non-CPAP), CPAP treatment can reduce high TNF-α (WMD [95%CI]= −4.44 [−4.81, −4.07]pg/ml, <i>p</i> &lt; .00001) and CRP (WMD [95%CI]= −0.91 [−1.65, −0.17] mg/l, <i>p</i> = .02) in OSA. Moreover, the primary MR analysis by IVW showed that OSA was the genetically predicted cause of elevated CRP (estimate: 0.095; 95% CI, [0.010–0.179]; <i>p</i> = .029) using six SNPs as the instrument variable, which were repeated by weighted median (estimate: 0.053; 95% CI, [0.007, 0.100]; <i>p</i> =.024) and MR RAPS (estimate: 0.109; 95% CI, [0.079, 0.140]; <i>p</i> = 1.98x10<sup>−12</sup>). Besides, the causal effect from elevated CRP on increased OSA risk was almost significant by IVW (OR:1.053; 95% CI, [1.000, 1.111]; <i>p</i> = .053). However, there were no causal associations between TNF-α and OSA from both directions. Increased CRP and TNF-α were associated with OSA severity and sensible to CPAP treatment. Also, OSA had a suggestive causal effect on elevated CRP.
DOI: 10.6084/m9.figshare.19962683.v2
title: The causal relationships between obstructive sleep apnea and elevated CRP and TNF-α protein levels

description: Obstructive sleep apnea (OSA) and inflammation are closely related. This study aimed to evaluate the associations and causal effect between C-reactive protein (CRP) and tumour necrosis factor-alpha (TNF-α) levels and OSA. Pooled analysis was conducted to compare the expression differences of CRP and TNF-α between OSA patients with different severity and controls, and between continuous positive airway pressure (CPAP) and non-CPAP interventions for OSA patients. Using published GWAS summary statistics, we conducted a bidirectional two-sample Mendelian Randomization (MR) to estimate the causal relationships between CRP and TNF-α levels and OSA risk. Effect estimates were evaluated using inverse-variance weighted (IVW) as primary method, and several other MR methods as sensitivity analysis. Both TNF-α (WMD [95%CI] = 5.86 [4.80–6.93] pg/ml, <i>p</i> &lt; .00001) and CRP (WMD [95%CI] = 2.66 [2.15–3.17] mg/L, <i>p</i> &lt; .00001), showed a significant increase in OSA patients compared with controls and this increasing trend was associated with OSA severity. Besides, compared to blank control (non-CPAP), CPAP treatment can reduce high TNF-α (WMD [95%CI]= −4.44 [−4.81, −4.07]pg/ml, <i>p</i> &lt; .00001) and CRP (WMD [95%CI]= −0.91 [−1.65, −0.17] mg/l, <i>p</i> = .02) in OSA. Moreover, the primary MR analysis by IVW showed that OSA was the genetically predicted cause of elevated CRP (estimate: 0.095; 95% CI, [0.010–0.179]; <i>p</i> = .029) using six SNPs as the instrument variable, which were repeated by weighted median (estimate: 0.053; 95% CI, [0.007, 0.100]; <i>p</i> =.024) and MR RAPS (estimate: 0.109; 95% CI, [0.079, 0.140]; <i>p</i> = 1.98x10<sup>−12</sup>). Besides, the causal effect from elevated CRP on increased OSA risk was almost significant by IVW (OR:1.053; 95% CI, [1.000, 1.111]; <i>p</i> = .053). However, there were no causal associations between TNF-α and OSA from both directions. Increased CRP and TNF-α were associated with OSA severity and sensible to CPAP treatment. Also, OSA had a suggestive causal effect on elevated CRP.
DOI: 10.6084/m9.figshare.21360465
title: Risk of dry eye in headache patients: a systematic review and meta-analysis

description: The objective of this meta-analysis was to identify whether headache increase the risk of dry eye disease (DED). PubMed, Web of Science, Cochrane Library and EMBASE databases were searched for relevant studies. The odds ratio (OR) of DED in all-cause headache was calculated <i>via</i> Stata software. To explore the source of heterogeneity, subgroup and sensitivity analyses were conducted. Funnel plots and Egger’s test were performed to assess publication bias. This meta-analysis included 11 studies. Pooled analysis indicated that all-cause headache was related to a higher risk of DED (OR = 1.586, 95% CI : 1.409–1.785, <i>I</i><sup>2</sup> = 89.3%, <i>p</i> &lt; .001). Migraine headache, tension headache and cluster headache were all related to a higher risk of DED (OR = 1.503, 95% CI: 1.369–1.650, <i>I</i><sup>2</sup> = 81.8%, <i>p</i> &lt; .001; OR = 1.610, 95% CI: 1.585–1.635, <i>p</i> &lt; .001; OR = 2.120, 95% CI: 1.104–4.073, <i>p =</i> .024), respectively. The risk of DED in case–control studies was slightly higher than in cross-sectional studies and cohort study (OR = 1.707, 95% CI: 1.291–2.258, <i>I</i><sup>2</sup> = 85.0%, <i>p</i> &lt; .001; OR = 1.600, 95% CI: 1.590–1.610, <i>I<sup>2</sup></i> = 0.0%, <i>p</i> &lt; .001; OR = 1.440, 95% CI: 1.096–1.893, <i>p =</i> .009), respectively. Subgroup analysis in territory type showed that all-cause headache in America, Europe, Asia and Oceania were all related to a higher risk of DED. This study indicates that headache is related to a higher risk of DED, especially in the migraine patients. These results suggest that headaches should be regarded as an independent risk factor for DED.KEY MESSAGESIn this meta-analysis, 11 studies (one cohort study, four case–control studies and six cross-sectional studies) covering 3,575,957 individuals were included.Pooled analysis indicated that all-cause headache was related to a higher risk of dry eye (OR = 1.586, 95% CI: 1.409–1.785, <i>I</i><sup>2</sup> = 89.3%, <i>p</i> &lt; .001).These results suggest that headaches should be regarded as an independent risk factor for dry eye. In this meta-analysis, 11 studies (one cohort study, four case–control studies and six cross-sectional studies) covering 3,575,957 individuals were included. Pooled analysis indicated that all-cause headache was related to a higher risk of dry eye (OR = 1.586, 95% CI: 1.409–1.785, <i>I</i><sup>2</sup> = 89.3%, <i>p</i> &lt; .001). These results suggest that headaches should be regarded as an independent risk factor for dry eye.
DOI: 10.6084/m9.figshare.21360465.v1
title: Risk of dry eye in headache patients: a systematic review and meta-analysis

description: The objective of this meta-analysis was to identify whether headache increase the risk of dry eye disease (DED). PubMed, Web of Science, Cochrane Library and EMBASE databases were searched for relevant studies. The odds ratio (OR) of DED in all-cause headache was calculated <i>via</i> Stata software. To explore the source of heterogeneity, subgroup and sensitivity analyses were conducted. Funnel plots and Egger’s test were performed to assess publication bias. This meta-analysis included 11 studies. Pooled analysis indicated that all-cause headache was related to a higher risk of DED (OR = 1.586, 95% CI : 1.409–1.785, <i>I</i><sup>2</sup> = 89.3%, <i>p</i> &lt; .001). Migraine headache, tension headache and cluster headache were all related to a higher risk of DED (OR = 1.503, 95% CI: 1.369–1.650, <i>I</i><sup>2</sup> = 81.8%, <i>p</i> &lt; .001; OR = 1.610, 95% CI: 1.585–1.635, <i>p</i> &lt; .001; OR = 2.120, 95% CI: 1.104–4.073, <i>p =</i> .024), respectively. The risk of DED in case–control studies was slightly higher than in cross-sectional studies and cohort study (OR = 1.707, 95% CI: 1.291–2.258, <i>I</i><sup>2</sup> = 85.0%, <i>p</i> &lt; .001; OR = 1.600, 95% CI: 1.590–1.610, <i>I<sup>2</sup></i> = 0.0%, <i>p</i> &lt; .001; OR = 1.440, 95% CI: 1.096–1.893, <i>p =</i> .009), respectively. Subgroup analysis in territory type showed that all-cause headache in America, Europe, Asia and Oceania were all related to a higher risk of DED. This study indicates that headache is related to a higher risk of DED, especially in the migraine patients. These results suggest that headaches should be regarded as an independent risk factor for DED.KEY MESSAGESIn this meta-analysis, 11 studies (one cohort study, four case–control studies and six cross-sectional studies) covering 3,575,957 individuals were included.Pooled analysis indicated that all-cause headache was related to a higher risk of dry eye (OR = 1.586, 95% CI: 1.409–1.785, <i>I</i><sup>2</sup> = 89.3%, <i>p</i> &lt; .001).These results suggest that headaches should be regarded as an independent risk factor for dry eye. In this meta-analysis, 11 studies (one cohort study, four case–control studies and six cross-sectional studies) covering 3,575,957 individuals were included. Pooled analysis indicated that all-cause headache was related to a higher risk of dry eye (OR = 1.586, 95% CI: 1.409–1.785, <i>I</i><sup>2</sup> = 89.3%, <i>p</i> &lt; .001). These results suggest that headaches should be regarded as an independent risk factor for dry eye.
DOI: 10.15468/dl.k69fm7
title: Occurrence Download

description: A dataset containing 37285 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Papaver cambricum"
 ]
}

 The dataset includes 37285 records from 472 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0042122-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.